Decourt 2020 / MCLENA-1

Study ID(s) and Acronym(s)
MCLENA-1
Current Status of Trial
Ongoing
Study Aim
Treatment MCI
Study Design
RCT
Blinding
Unclear
Intervention type
Pharmacological
Intervention
Lenalidomide // Plavebo
Dosage and Duration
In this Phase II, proof-of mechanism study, 30 amnestic mild cognitive impairment (aMCI) subjects will be treated with lenalidomide at 10 mg/day for 12 months on a 1:1 ratio, followed by a 6 months washout period.
Absolute Number of Participants
30
Health Status/Diagnosis
Mild Cognitive Impairment (MCI) // aMCI
Primary outcomes
Cognition